Histidyl-tRNA synthetase-Fc conjugates

US10093915B2 · kind B2 · utility

Assignee

• aTyr Pharma, Inc. · US

Inventors

• Chi-Fang Wu · San Diego, US
• Darin Lee · San Diego, US
• Jeffry D. Watkins · Encinitas, US
• Kristi Helen Piehl · San Diego, US
• Kyle P. Chiang · Irvine, US
• Marc Thomas · Vista, US
• Minh-Ha Do · San Diego, US
• Ying Buechler · Carlsbad, US
• John D. Mendlein · Encinitas, US

Key dates

• Filing date: Jan 25, 2017
• Grant date: Oct 9, 2018
• Expiry date: Mar 7, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.